WHY DID PEPTIDE SCIENCES SHUT DOWN OVERNIGHT?

The inside story: FDA, Big Pharma lawsuits, and the quality failures that brought down a $7.4M/month empire.

At 2:00 PM Eastern on March 6, 2026, a business generating $7.4 million per month posted three sentences on its homepage and went dark. No warning. No refund plan. No explanation. Peptide
Sciences — the largest gray-market research peptide vendor in the United States — was gone. Not raided, not shut by court order, but voluntarily. That quiet, deliberate exit tells you everything about what was coming next.

EDUCATIONAL DISCLAIMER

FOR RESEARCH AND EDUCATIONAL PURPOSES ONLY

This white paper discusses regulatory enforcement actions and market events for educational purposes only. Nothing here constitutes legal or medical advice. The regulatory landscape is changing rapidly — conditions reflect March 2026. Consult a healthcare provider and attorney for guidance specific to your situation. LiveWell Peptides does not sell gray-market research peptides.

WHO WAS PEPTIDE SCIENCES — AND WHY DID IT MATTER?

Peptide Sciences was not a garage operation. It was the dominant force in the US gray-market research peptide space — a decade-old company based in Henderson, Nevada, that offered hundreds of compounds under “for research use only” labeling.

At its peak it moved over one million website visitors per month. Its December 2025 sales hit $7.4 million — in a single month. The catalog covered everything researchers wanted: BPC-157,
TB-500, semaglutide, tirzepatide, retatrutide, growth hormone secretagogues, anti-aging peptides, and more. Claimed purity? 99%+, with WHO/GMP and ISO-certified manufacturing partners.

When a company this size disappears with three sentences and no warning, the explanation is not bad luck. It is a calculated exit from a landscape that had become impossible to survive.

THE THREE-SENTENCE GOODBYE

“VOLUNTARY” WAS A CAREFUL CHOICE OF WORDS

The Peptide Sciences announcement described the closure as “voluntary.” Healthcare law firm Frier Levitt translated what that likely means: the company’s legal team advised that the risk of
forced closure — complete with raids, seized assets, and criminal exposure — outweighed any benefit of continuing to operate. “Voluntary” is what you call it when the alternative is worse.

THREE FORCES THAT COLLAPSED THE GRAY-MARKET MODEL

The shutdown was not triggered by one dramatic moment. It was the endpoint of three separate pressures that built simultaneously over 24 months and made the gray-market model mathematically unsustainable.

FORCE ONE — THE FDA WENT FROM LETTERS TO BOOTS ON THE GROUND

For years, “research use only” functioned like a magic shield. Vendors slapped the label on vials of human-consumable compounds and the FDA mostly sent letters. That era ended in June 2025 when federal agents physically walked into Amino Asylum’s warehouse and the site went dark the same afternoon.

The shift was ideological, not just tactical. By 2025, the FDA’s position had hardened: a molecule with physiological effects on humans is a drug. A label does not change what a molecule does.
Frier Levitt healthcare attorneys were telling their clients that the RUO disclaimer provided “essentially zero legal protection.” The warning letters that had been routine since 2023 now came with DOJ and FBI coordination.

THE SCIENCE SAYS

THE “RESEARCH USE ONLY” DEFENSE WAS ALWAYS A LEGAL FICTION

The FDA has been consistent since 1938: if a compound has pharmacological activity in humans, it requires approval as a drug — regardless of the label. The research peptide industry built
a billion-dollar market on the hope that the FDA would not enforce this position aggressively. By 2025, that hope was exhausted.
FORCE TWO — ELI LILLY AND NOVO NORDISK DECLARED LEGAL WAR
The pharmaceutical companies that invented the GLP-1 revolution were watching gray-market vendors sell imitations of their most profitable products. Tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) were being sold online for a fraction of pharmacy prices. The response was fast, overwhelming, and federal.

In March 2024, Eli Lilly filed a complaint with the US International Trade Commission against 12 vendors. By January 2025, the ITC issued a General Exclusion Order — blocking all trademark-infringing tirzepatide imports from entering the country. Any vendor selling tirzepatide after that date was not in a regulatory gray zone. They were violating a federal order.

Novo Nordisk ran a parallel campaign against compounded semaglutide. When the FDA declared the semaglutide shortage resolved in February 2025, the legal exemption that had allowed hundreds of pharmacies to produce GLP-1 analogs legally simply ceased to exist.

DID YOU KNOW?

THE GLP-1 GRAY MARKET WAS WORTH $328 MILLION — THEN IT WAS CUT OFF

US peptide imports from China reached $328 million in the first 9 months of 2025 — nearly double the prior year. Much of that was gray-market GLP-1 compounds. When the ITC exclusion order, FDA
shortage resolution, and DOJ prosecution campaign converged, that revenue stream did not slow down. It was severed.

FORCE THREE — THE QUALITY DATA WENT PUBLIC AND IT WAS DAMAGING

The third force was internal — and perhaps the most humiliating. Independent testing platform Finnrick Analytics had been systematically testing Peptide Sciences products and publishing
the results publicly. The data was not just imperfect. For some flagship products, it was disqualifying.

Retatrutide was Peptide Sciences’ most hyped product — the cutting-edge triple agonist that biohackers were paying premium prices to obtain. Every single one of 37 tested samples failed. A
counterfeit was flagged in November 2025. The company never publicly responded to the results.

A vendor can survive FDA warning letters. It can survive legal pressure from pharmaceutical companies. But surviving all three simultaneously — while independent labs are publicly documenting that your flagship product is potentially counterfeit — that is a different calculation entirely.

THE 24-MONTH ENFORCEMENT TIMELINE

The overnight shutdown was actually the final scene of a two-year story. Here is how it unfolded, event by event:

THE CRUEL IRONY

THE REVERSAL CAME ONE WEEK TOO LATE

On February 27, 2026 — exactly one week before Peptide Sciences closed — HHS Secretary RFK Jr. announced on the Joe Rogan Experience that approximately 14 of 19 restricted Category 2 peptides would return to Category 1, restoring legal access through licensed compounding pharmacies. He called the original FDA ban “illegal” and admitted it “created the gray market.” But as legal experts immediately noted: a podcast announcement is not a regulatory update. No formal rule had changed. The market damage was already done.

WHAT ABOUT SCIENCE.BIO?

Science.bio told a quieter but parallel story. Founded in 2019 as the successor to IRC.Bio (which the FDA had pressured to close over SARMs in 2018), Science.bio built a loyal following through genuine quality commitment — independent third-party testing, transparent COA documentation, and a catalog that included SARMs, nootropics, and research peptides.

Science.bio actually did things better than most gray-market vendors. Their testing was more transparent. Their documentation was more rigorous. And in January 2026, they still closed. Their
farewell email said: “Getting more difficult and more expensive.”

Unlike Peptide Sciences, Science.bio refunded or fulfilled all outstanding orders before closing — a meaningful distinction. But the conclusion was the same: the regulatory and legal
environment had made the business model unviable, even when you played by the rules.

THE LESSON FROM SCIENCE.BIO

DOING THINGS RIGHT WAS NOT ENOUGH TO SURVIVE

Science.bio had arguably the best quality documentation in the gray-market peptide space. Third-party testing. Batch-specific COAs. Transparent sourcing. They closed anyway. The issue was
not primarily quality — it was the legal framework itself. “Research use only” stopped being a viable business category. That affected the bad actors and the good ones equally.

THE SAFETY REALITY THE INDUSTRY DID NOT WANT TO TALK ABOUT

The regulatory crackdown was not purely about intellectual property or market control. There was a genuine safety problem — and the data behind it was stark.

In 2025, two women were hospitalized and placed on ventilators after receiving peptide injections at a longevity conference in Las Vegas. A ProPublica investigation covered the incident. These
were not fringe cases — they were the visible edge of a much larger iceberg.

The TikTok videos of biohackers reconstituting unverified vials on kitchen counters without gloves were not edge cases either. Online peptide advertising surged 678% from 2022 to 2024. Chinese
imports nearly doubled to $328 million in 2025. More volume through less regulated channels produced exactly the outcomes that regulators had warned about.

WHAT THIS MEANS IF YOU HAVE PRODUCTS FROM THESE VENDORS

QUALITY VARIED DRAMATICALLY — AND RECONSTITUTED PEPTIDES DEGRADE FAST

Finnrick’s testing showed wild inconsistency across the Peptide Sciences catalog. BPC-157 scored an A (7.8/10). Retatrutide scored a failing E across 37 samples. If you have reconstituted
vials: they degrade within 30 days even when refrigerated. Lyophilized powder stored at proper temperatures retains potency longer. If you have pending orders or store credit from Peptide
Sciences: contact your credit card company immediately. Chargebacks are typically available within 60-120 days of the transaction.

WHAT HAPPENS NEXT — THE MARKET IS SPLITTING

The compounds are not disappearing. The market is restructuring — from an unregulated gray zone into two distinct, very different channels.

The RFK Category 1 reclassification — when formally published — will restore legal access to approximately 14 peptides including BPC-157, TB-500, epithalon, selank, semax, and others through
licensed compounding pharmacies. This is not a return to the gray market. It requires a physician’s prescription and a licensed compounder. The days of buying injectable peptides online
without medical oversight are over.

PRACTICAL GUIDE — WHAT TO DO RIGHT NOW<h/h2>

IF YOU HAD PENDING ORDERS WITH PEPTIDE SCIENCES:

• File a credit card chargeback immediately — use reason code “merchant ceased operations”
• Document everything: order confirmations, account balances, payment receipts
• Most cards allow chargebacks 60-120 days from transaction date — do not wai
• If chargeback fails, file a consumer protection complaint with your state attorney general

IF YOU WERE RELYING ON GRAY-MARKET COMPOUNDS FOR ONGOING RESEARCH:

• Monitor FDA.gov and HHS.gov for formal publication of the Category 1 reclassification
• When official, licensed compounding pharmacies with a physician’s prescription is the path
• Verify any new vendor with independent third-party COAs from accredited labs — not in-house testing
• Require HPLC purity, mass spectrometry identity, AND endotoxin testing documentation
• Avoid any vendor still selling tirzepatide imports — ITC exclusion order remains in full effect

The bottom line: The compounds that researchers depend on are not gone — they are moving into a more regulated channel. That transition is disruptive. It requires a physician relationship and a prescription. But it also provides something the gray market never could: verified quality, legal protection, and medical oversight. For the peptide research community, this is not the end of the story. It is the end of the beginning.

THE BIGGER PICTURE

THE ERA OF “RESEARCH USE ONLY” IS OVER. WHAT REPLACES IT MATTERS MORE.

Peptide Sciences built something remarkable — a massive, trusted marketplace for compounds that millions of people genuinely wanted access to. The regulatory framework that destroyed it was
blunt, imperfect, and sometimes contradictory. But the safety failures it exposed were real. The path forward is more friction, more oversight, and more legitimacy — which ultimately serves the
researchers and patients who depend on these compounds most.

SOURCES & REFERENCES

1. PeptideProtocolWiki. Peptide Sciences Shut Down: What Happened and What It Means for the Industry. March 2026.
2. PeptidesExplorer. Peptide Sciences Shut Down: What Happened (March 2026). March 2026.
3. Peptide Examiner. Why Did Peptide Sciences Close Down? March 2026.
4. Peplogix. What Happened to Peptide Sciences? Inside the Shutdown. March 2026.
5. Muscle and Brawn. Peptide Sciences Shut Down: What Happened and Where to Buy Now. March 2026.
6. All About Peptides. Peptide Sciences Pulls the Plug: Major Research Supplier Shuts Down. March 2026.
7. Rapamycin.news. Science.bio Closes. January 2026.
8. Finnrick Analytics. Independent testing of Peptide Sciences products — 123 samples, 10 peptides. Dec 2024–Mar 2026.
9. Grips Intelligence. Peptide Sciences e-commerce analytics ($7.4M December 2025 sales). March 2026.
10. U.S. International Trade Commission. General Exclusion Order — Certain Tirzepatide Products. January 2025.
11. FDA. Warning Letters to Research Peptide Vendors. December 2024.
12. FDA. GLP-1 Drug Shortage Resolution Announcement. February 2025.
13. FDA. Enforcement Action — Amino Asylum Warehouse. June 2025.
14. FDA. Warning Letters to GLP-1 Compounders (50+ letters). September 2025.
15. DOJ. Paradigm Peptides — Guilty Pleas Entered. December 2025.
16. Kennedy RFK Jr. Category 1 Peptide Reclassification Announcement. Joe Rogan Experience. February 27, 2026.
17. Frier Levitt Healthcare Law. Research Use Only Disclaimer Analysis. 2025.
18. LegitScript. Online Peptide Advertising Growth: 678% from 2022 to 2024. 2024.
19. U.S. Customs. Chinese Peptide/Hormone Compound Imports: $328 million, Q1-Q3 2025. 2025.
20. Huang T, et al. Quality Assessment of Internet-Purchased Research Peptides. Drug Test Anal. 2024.
21. FDA. Bulk Drug Substances Category 2 List. Updated 2024.

FOR RESEARCH AND EDUCATIONAL PURPOSES ONLY • This publication is for educational purposes only. It does not constitute legal or medical advice. The regulatory landscape described reflects conditions as of March 2026 and is subject to rapid change. LiveWell Peptides does not sell gray-market research peptides. All compounds mentioned are discussed for educational purposes only. Consult a licensed healthcare provider and attorney for any decisions related to peptide access or regulatory compliance.